Literature DB >> 21200291

Surgical treatment of osteomyelitis.

George Cierny1.   

Abstract

Chronic osteomyelitis is refractory to nonsurgical treatment due to a resilient, infective nidus that harbors sessile, matrix-protected pathogens bound to substrate surfaces within the wound. Curative treatment mandates physical (surgical) removal of the biofilm colony, adjunctive use of antibiotics to eliminate residual phenotypes, and efforts to optimize the host response throughout therapy. Patient selection, therapeutic options, and the treatment format are determined by the Cierny/Mader staging system, while reconstruction is governed by the integrity/stability of the affected bone(s) and quality/quantity parameters of the soft-tissue envelope.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21200291     DOI: 10.1097/PRS.0b013e3182025070

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  32 in total

1.  Chitosan coating to enhance the therapeutic efficacy of calcium sulfate-based antibiotic therapy in the treatment of chronic osteomyelitis.

Authors:  Karen E Beenken; James K Smith; Robert A Skinner; Sandra G Mclaren; William Bellamy; M Johannes Gruenwald; Horace J Spencer; Jessica A Jennings; Warren O Haggard; Mark S Smeltzer
Journal:  J Biomater Appl       Date:  2014-05-21       Impact factor: 2.646

2.  Bioactive glass as dead space management following debridement of type 3 chronic osteomyelitis.

Authors:  Willem Oosthuysen; Rudolph Venter; Yashwant Tanwar; Nando Ferreira
Journal:  Int Orthop       Date:  2019-11-08       Impact factor: 3.075

3.  Chronic calcaneal osteomyelitis associated with soft-tissue defect could be successfully treated with platelet-rich plasma: a case report.

Authors:  Hsin-Fu Wang; You-Shui Gao; Ting Yuan; Xiao-Wei Yu; Chang-Qing Zhang
Journal:  Int Wound J       Date:  2012-02-24       Impact factor: 3.315

4.  Evaluation of Antibiotics Active against Methicillin-Resistant Staphylococcus aureus Based on Activity in an Established Biofilm.

Authors:  Daniel G Meeker; Karen E Beenken; Weston B Mills; Allister J Loughran; Horace J Spencer; William B Lynn; Mark S Smeltzer
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

5.  Osteomyelitis due to multiple rare infections in a patient with idiopathic CD4 lymphocytopenia.

Authors:  Nitin Gupta; Sayantan Banerjee; Rohini Sharma; Shambo Guha Roy; Trupti M Shende; Mohammed Tahir Ansari; Gagandeep Singh; Neeraj Nischal; Naveet Wig; Manish Soneja
Journal:  Intractable Rare Dis Res       Date:  2017-08

6.  Antibiotic cement-coated locking plate as a temporary internal fixator for femoral osteomyelitis defects.

Authors:  Xin Yu; Hongri Wu; Jianhua Li; Zhao Xie
Journal:  Int Orthop       Date:  2016-08-13       Impact factor: 3.075

Review 7.  The role of biofilm on orthopaedic implants: the "Holy Grail" of post-traumatic infection management?

Authors:  C Mauffrey; B Herbert; H Young; M L Wilson; M Hake; P F Stahel
Journal:  Eur J Trauma Emerg Surg       Date:  2016-06-04       Impact factor: 3.693

8.  A modified staging system for chronic osteomyelitis.

Authors:  Leonard Charles Marais; Nando Ferreira; Colleen Aldous; Benn Sartorius; Theo Le Roux
Journal:  J Orthop       Date:  2015-06-12

9.  Novel Bone-Targeting Agent for Enhanced Delivery of Vancomycin to Bone.

Authors:  Zaineb A F Albayati; Manjula Sunkara; Suzannah M Schmidt-Malan; Melissa J Karau; Andrew J Morris; James M Steckelberg; Robin Patel; Philip J Breen; Mark S Smeltzer; K Grant Taylor; Kevyn E Merten; William M Pierce; Peter A Crooks
Journal:  Antimicrob Agents Chemother       Date:  2015-12-14       Impact factor: 5.191

10.  Use of xylitol to enhance the therapeutic efficacy of polymethylmethacrylate-based antibiotic therapy in treatment of chronic osteomyelitis.

Authors:  Karen E Beenken; Laura Bradney; William Bellamy; Robert A Skinner; Sandra G McLaren; M Johannes Gruenwald; Horace J Spencer; James K Smith; Warren O Haggard; Mark S Smeltzer
Journal:  Antimicrob Agents Chemother       Date:  2012-09-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.